Lung cancer screening by low-dose CT scan in France - final results of the DEP KP80 study after three rounds

Sep 21, 2026

Lung cancer screening with low-dose computed tomography (LDCT) has reduced lung cancer mortality and overall mortality in prior randomised controlled trials, yet organised screening in France remains difficult. This single-arm prospective study evaluated feasibility and efficacy of LDCT screening in a real-life French administrative territory. Participants aged 55–74 and with significant smoking history underwent baseline and subsequent annual rounds, with results assessed across three screening iterations.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages14

Reading Time35 min

AccessFree to download

Summary

Background

Methods

Findings

Interpretation

Funding

Research in context

Evidence before this study

Added value of this study

Implications of all the available evidence

Articles Lung cancer screening by low-dose CT scan in France: ﬁnal results of the DEP KP80 study after three rounds Olivier Leleu,a,∗ Nicolas Storme,b Damien Basille,b,c Marianne Auquier,d Valerie Petigny,e Pascal Berna,f Alexia Letierce,g Sebastien Couraud,h Julie de Bermont,h Bernard Milleron,i and Vincent Jounieauxb,c aDepartment of Pulmonology and Thoracic Oncology Centre Hospitalier Abbeville, Abbeville Cedex, France bDepartment of Pulmonology and Thoracic Oncology CHU Amiens, Amiens, France cAGIR Unit, University of Picardie Jules Verne, Amiens, France dDepartment of Radiology CHU Amiens, Amiens, France eCRCDC 6 Rue Colbert Amiens, France fDepartment of Thoracic Surgery CHU Amiens, France gBiostatistician, QualityStat, Morangis, France hRespiratory Medicine Department, CHU Lyon Sud, Lyon, France iIntergroupe Francophone de Cancérologie Thoracique, Paris, France Summary Background In prior randomised controlled trials, lung cancer screening using low-dose computed tomography (LDCT) has been shown to reduce lung cancer mortality and overall mortality. Despite these results, organised screening in France remains a challenge. This study assessed the feasibility and efﬁcacy of lung cancer screening within a real-life context in a French administrative territory. Methods DEP KP80 was a single-arm prospective study. Participants aged between 55 and 74 years, smokers or former smokers of ≥30 pack-years, were recruited. An annual LDCT scan was scheduled and three rounds were performed. Subjects were selected by general practitioners or pulmonologists, who checked the inclusion criteria and prescribed the CT scan. Findings Between March 2016 and February 2020, 1254 participants were enrolled. Overall, 945 (75.4%) participants underwent baseline LDCT (T0), 376 (42.8%) completed the ﬁrst round (T1) and 270 (31%) the second (T2) one. Fortytwo lung cancers were diagnosed, 30 cancers (71.4%) were stage I or II and 34 cancers (80.9%) were treated surgically. In this study, the overall positive predictive value for a positive screening was 48%(95% CI 37–59) and the negative predictive value 100%(95% CI 100–100) . Interpretation This study demonstrated the feasibility and efﬁcacy oflung cancer screening in a real-life context with most lung cancers diagnosed at an early stage and surgically removed. Our results also highlighted the importance of participation in each round, underlining the fact that optimising organisation is a major goal. Funding Agence Régionale de Santé de Picardie, La Ligue contre le cancer, le Conseil Départemental de la Somme, and AstraZeneca. Copyright © 2024 The Author(s) . Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license ([http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)). Keywords: Screening; Lung cancer; Early detection; Low-dose computed tomography (LDCT) scan; Real life Introduction Despite major therapeutic advances in recent years, lung cancer remains the world’s leading cause of cancerrelated death, accounting for almost 2 million deaths every year, which is more than deaths related to breast and colon cancer combined.1 The most powerful prognostic factor in lung cancer is its tumour, node, metastasis (TNM) classiﬁcation, with 5-year survival rates ranging from 92% for Stage IA to 10% for Stage IVA.2, 3 Unfortunately, lung cancer is usually diagnosed at an advanced stage. The recent French KBP-2020 study showed that, out of 8999 new lung cancer cases, only eBioMedicine 2024;109: 105396 Published Online 12 October 2024 [https://doi.org/10](https://doi.org/10) . 1016/j.ebiom.2024 . 105396 *Corresponding author. E-mail address: [leleu.olivier@ch-abbeville.fr](leleu.olivier@ch-abbeville.fr) (O. Leleu). [www.thelancet.com Vol](www.thelancet.com Vol) 109 November, 2024 1 Articles Research in context Evidence before this study Lung cancer is a major public health prob

FAQs

What was the goal of the DEP KP80 study in France?

To assess the feasibility and efficacy of lung cancer screening using low-dose CT in a real-life setting within a French administrative territory.

Who were the participants and how was screening delivered?

Participants aged 55–74, including current or former smokers with at least 30 pack-years, were recruited; annual LDCT scans were scheduled and three rounds were performed.

What were the main findings after three rounds of screening?

Among 1254 enrolled participants, baseline uptake was 75.4% and subsequent completion declined. Forty-two lung cancers were diagnosed, most at early stages, and the positive predictive value for a positive screen was 48%.

Sep 21, 2026

Upload by Genevieve